News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: Treatment With Pradaxa® Associated With Better Patient Outcomes After a Major Bleeding Event Compared to Warfarin


12/10/2012 9:58:40 AM

INGELHEIM, Germany--(BUSINESS WIRE)-- Results from a new post-hoc analysis of the landmark RE-LY®i trial show that in patients experiencing a major bleeding event, treatment with Pradaxa® (dabigatran etexilate) was associated with lower mortality and a shorter length of stay in intensive care compared to warfarin. In a pooled post-hoc analysis of five Phase III trials with Pradaxa®, the data show a clear trend towards a better prognosis after a major bleed with Pradaxa® than with warfarin. These new data were presented at the American Society of Hematology (ASH) Annual Meeting 2012 in Atlanta, Georgia, USA.1 In the RE-LY® trial, rates of major bleeding events were similar with Pradaxa® 150 mg when compared to warfarin and significantly lower for Pradaxa® 110 mg.2,3

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES